Could a new drug help stroke patients recover better?
NCT ID NCT07495722
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests the safety of a drug called pegcetacoplan (Empaveli) in 20 adults who have had a stroke from a large clot and already had a procedure to remove it. The drug aims to reduce swelling and inflammation that can occur when blood flow returns. Participants receive three doses and are followed for 90 days to check for side effects and recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegcetacoplan (Empaveli)
- What this could lead to
- If safe, this could point toward a treatment that reduces brain swelling and improves recovery after a stroke.
- What could go wrong
- This is a very early Phase 1 safety trial with only 20 people. It is not designed to prove the drug works, and side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?